Association of BRCA Mutations and Anti-m üllerian Hormone Level in Young Breast Cancer Patients

Conclusions: Breast cancer patients with BRCA mutation have significantly lower serum AMH level. Fertility preservation should be considered more aggressively in young breast cancer patients with BRCA mutation. Introduction BRCA mutations are associated with high risk of breast and ovarian cancer in reproductive-aged women (1, 2). The lifetime risks of breast and ovarian cancer are 65 and 39%, respectively, in BRCA1 mutation carriers and 45 and 11% in BRCA2 mutation carriers (3). In addition to cancer risk, it has been suggested that BRCA mutation may be related to decreased ovarian reserve, due to BRCA's function in repairing double-strand DNA breaks (4). Several studies have demonstrated significantly decreased serum anti-Müllerian hormone (AMH) level, a biomarker representing ovarian reserves (5), in BRCA mutation carriers (6–9). Moreover, in breast cancer patients who underwent ovarian stimulation for fertility-preservation, there was a higher rate of poor ovarian response (POR) in BRCA-mutation carriers compared to non-carriers (10, 11). However, some studies have found no difference in serum AMH level according to BRCA mutation status (12–15). Therefore, the association between BRCA mutation status and decreased ovarian reserve is not conclusive. In addition, only a few studies have shown a significant association between BRCA mutation and decreased ovarian reserve in young breast cancer patients (16, 17). Considering that it is...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research